A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
Clinical trial NCT06877533 · TERMINATED
Trial details
- NCT number
- NCT06877533
- Sponsor
- iTeos Belgium SA
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-07
- Primary completion
- 2025-07-10
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.